A one year longitudinal study in Multiple sclerosis patients evaluating multiparametric phenotyping of immune cell dynamics under ocrelizumab
Latest Information Update: 13 Dec 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Therapeutic Use
- 13 Dec 2021 New trial record
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis